Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
2007

Validation of Chromogenic In Situ Hybridisation for HER2 Status in Breast Cancer

Sample size: 211 publication Evidence: high

Author Information

Author(s): Marc van de Vijver, Michael Bilous, Wedad Hanna, Manfred Hofmann, Petra Kristel, Frédérique Penault-Llorca, Josef Rüschoff

Primary Institution: Netherlands Cancer Institute

Hypothesis

Can chromogenic in situ hybridisation (CISH) be validated against fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) for assessing HER2 status in breast cancer?

Conclusion

CISH is a reliable alternative to FISH for determining HER2 gene copy numbers in breast cancer specimens.

Supporting Evidence

  • 96% of high amplification cases by FISH scored positive by CISH.
  • 94% of FISH-negative cases had no amplification by CISH.
  • Inter-laboratory concordance was 95% for normal HER2 copy number.
  • 92% concordance for cases with HER2 copy numbers ≥ 6.
  • CISH showed 91% concordance with IHC for IHC-negative cases.
  • CISH was 100% concordant with high amplification cases by FISH.

Takeaway

This study shows that a new test called CISH works really well to check if breast cancer cells have a certain gene that can affect treatment.

Methodology

Five international pathology laboratories performed CISH, FISH, and IHC on breast cancer samples to compare results.

Limitations

The study included a limited number of low-level amplification cases, which are rare and technically challenging to assess.

Digital Object Identifier (DOI)

10.1186/bcr1776

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication